Search

Your search keyword '"Lukoye, Deus"' showing total 27 results
Start Over Author "Lukoye, Deus"
27 results on '"Lukoye, Deus"'

2. Tuberculosis Preventive Therapy among Persons Living with HIV, Uganda, 2016-2022

Author

Lukoye, Deus, Gustavson, Gail, Namuwenge, Proscovia M., Muchuro, Simon, Birabwa, Estella, Dejene, Seyoum, Ssempiira, Julius, Kalamya, Julius N., Baveewo, Steven, Ferroussier-Davis, Odile, Mills, Lisa A., Dirlikov, Emilio, Nelson, Lisa J., and Turyahabwe, Stavia

Subjects
Tuberculosis -- Prevention -- Statistics -- Care and treatment, HIV patients -- Care and treatment -- Statistics, Health
Abstract

Tuberculosis (TB) is the leading cause of illness and death globally among persons living with HIV (PLHIV) (1,2). In 2021, among [approximately equal to] 38.4 million PLHIV worldwide, 703,000 TB [...]

Published
2023
Full Text
View/download PDF

3. Treatment Outcomes for Tuberculosis Infection and Disease Among Persons Deprived of Liberty, Uganda, 2020

Author

Lukoye, Deus, primary, Kalamya, Julius N., additional, Awor, Anna Colletar, additional, Gustavson, Gail, additional, Kabanda, Joseph, additional, Ferroussier-Davis, Odile, additional, Kajoba, Charles, additional, Kanyamibwa, Azaria, additional, Marungu, Leonard, additional, Turyahabwe, Stavia, additional, Muchuro, Simon, additional, Mills, Lisa, additional, Dirlikov, Emilio, additional, and Nelson, Lisa J., additional

Published
2024
Full Text
View/download PDF

5. Loss to Follow-Up Among People Living with HIV on Tuberculosis Preventive Treatment at Four Regional Referral Hospitals, Uganda, 2019–2021

Author

Nsubuga, Edirisa Juniour, primary, Lukoye, Deus, additional, Kabwama, Steven Ndugwa, additional, Migamba, Stella Martha, additional, Komakech, Allan, additional, Sarah, Elayete, additional, Nampeera, Rose, additional, Nakazzi, Rashida, additional, Magona Nerima, Saharu, additional, Kirabo, Jireh, additional, Bulage, Lilian, additional, Kwesiga, Benon, additional, and Ario, Alex Riolexus, additional

Published
2023
Full Text
View/download PDF

8. Factors associated with poor treatment outcomes among tuberculosis patients in Kyangwali Refugee Settlement, Uganda, 2016–2017

Author

Nguna, Joyce, primary, Okethwangu, Denis, additional, Kabwama, Steven Ndugwa, additional, Aliddeki, Dativa Maria, additional, Kironde, Susan Kizito, additional, Birungi, Doreen, additional, Eurien, Daniel, additional, Ario, Alex Riolexus, additional, Lukoye, Deus, additional, Kasozi, Julius, additional, and Cegielski, Peter J., additional

Published
2022
Full Text
View/download PDF

9. Uganda Public Health Fellowship Program's Contributions to the National HIV and TB Programs, 2015–2020

Author

Ario, Alex R., primary, Bulage, Lilian, additional, Wibabara, Yvette, additional, Muwereza, Peter, additional, Eurien, Daniel, additional, Kabwama, Steven N., additional, Kwesiga, Benon, additional, Kadobera, Daniel, additional, Turyahabwe, Stavia, additional, Musinguzi, Joshua B., additional, Wanyenze, Rhoda K., additional, Nasirumbi, Pamela M., additional, Lukoye, Deus, additional, Harris, Julie R., additional, Mills, Lisa A., additional, and Nelson, Lisa J., additional

Published
2022
Full Text
View/download PDF

10. Additional file 1 of Trends of notification rates and treatment outcomes of tuberculosis cases with and without HIV co-infection in eight rural districts of Uganda (2015 – 2019)

Author

Baluku, Joseph Baruch, Nanyonjo, Resty, Ayo, Jolly, Obwalatum, Jehu Eleazer, Nakaweesi, Jane, Senyimba, Catherine, Lukoye, Deus, Lubwama, Joseph, Ward, Jennifer, and Mukasa, Barbara

Abstract

Additional file 1: Appendix 1. Trends of TB treatment outcomes among men and women in rural Ugandadisaggregated by HIV status (2015 - 2019). Supplementary table 1. Population estimates for people with and without HIVin eight districts of rural Uganda.

Published
2022
Full Text
View/download PDF

24. Anti-Tuberculosis Drug Resistance among New and Previously Treated Sputum Smear-Positive Tuberculosis Patients in Uganda: Results of the First National Survey

Author

Lukoye, Deus, primary, Adatu, Francis, additional, Musisi, Kenneth, additional, Kasule, George William, additional, Were, Willy, additional, Odeke, Rosemary, additional, Kalamya, Julius Namonyo, additional, Awor, Ann, additional, Date, Anand, additional, and Joloba, Moses L., additional

Published
2013
Full Text
View/download PDF

26. The Mycobacterium tuberculosis Uganda II family and resistance to first-line anti-tuberculosis drugs in Uganda.

Author

Ezati, Nicholas, Lukoye, Deus, Wampande, Eddie M., Musisi, Kenneth, Kasule, George W., Cobelens, Frank G. J., Kateete, David P., and Joloba, Moses L.

Subjects
*MYCOBACTERIUM tuberculosis, *ANTITUBERCULAR agents, *EPIDEMIOLOGY, *HIV infections, *TUBERCULOSIS patients
Abstract

Background The global increase in the burden of multidrug-resistant tuberculosis (MDR-TB) underscores an urgent need for data on factors involved in generation and spread of TB drug resistance. We performed molecular analyses on a representative sample of Mycobacterium tuberculosis (MTB) isolates. Basing on findings of the molecular epidemiological study in Kampala, we hypothesized that the predominant MTB strain lineage in Uganda is negatively associated with anti-TB drug resistance and we set out to test this hypothesis. Methods We extracted DNA from mycobacterial isolates collected from smear-positive TB patients in the national TB drug resistance survey and carried out IS6110-PCR. To identify MTB lineages/sub lineages RT-PCR SNP was performed using specific primers and hybridization probes and the 'melting curve' analysis was done to distinguish the Uganda II family from other MTB families. The primary outcome was the distribution of the Uganda II family and its associations with anti-TB drug resistance and HIV infection. Results Out of the 1537 patients enrolled, MTB isolates for 1001 patients were available for SNP analysis for identification of Uganda II family, of which 973 (97%) had conclusive RT-PCR results. Of these 422 (43.4%) were of the Uganda II family, mostly distributed in the south west zone (55.0%; OR = 4.6 for comparison with other zones; 95% CI 2.83-7.57; p < 0.001) but occurred in each of the other seven geographic zones at varying levels. Compared to the Uganda II family, other genotypes as a group were more likely to be resistant to any anti-TB drug (ORadj =2.9; 95% CI 1.63-5.06; p = 0.001) or MDR (ORadj 4.9; 95% CI, 1.15-20.60; p = 0.032), even after adjusting for geographic zone, patient category, sex, residence and HIV status. It was commonest in the 25-34 year age group 159/330 (48.2%). No association was observed between Uganda II family and HIV infection. Conclusion The Uganda II family is a major cause of morbidity due to TB in all NTLP zones in Uganda. It is less likely to be resistant to anti-TB drugs than other MTB strain lineages. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

27. The T2 Mycobacterium tuberculosisGenotype, Predominant in Kampala, Uganda, Shows Negative Correlation with Antituberculosis Drug Resistance

Author

Lukoye, Deus, Katabazi, Fred A., Musisi, Kenneth, Kateete, David P., Asiimwe, Benon B., Okee, Moses, Joloba, Moses L., and Cobelens, Frank G. J.

Abstract

ABSTRACTSurveillance of the circulating Mycobacterium tuberculosiscomplex (MTC) strains in a given locality is important for understanding tuberculosis (TB) epidemiology. We performed molecular epidemiological studies on sputum smear-positive isolates that were collected for anti-TB drug resistance surveillance to establish the variability of MTC lineages with anti-TB drug resistance and HIV infection. Spoligotyping was performed to determine MTC phylogenetic lineages. We compared patients' MTC lineages with drug susceptibility testing (DST) patterns and HIV serostatus. Out of the 533 isolates, 497 (93.2%) had complete DST, PCR, and spoligotyping results while 484 (90.1%) participants had results for HIV testing. Overall, the frequency of any resistance was 75/497 (15.1%), highest among the LAM (34.4%; 95% confidence interval [CI], 18.5 to 53.2) and lowest among the T2 (11.5%; 95% CI, 7.6 to 16.3) family members. By multivariate analysis, LAM (adjusted odds ratio [ORadj], 5.0; 95% CI, 2.0 to 11.9; P< 0.001) and CAS (ORadj, 2.9; 95% CI, 1.4.0 to 6.3; P= 0.006) families were more likely to show any resistance than was T2. All other MTC lineages combined were more likely to be resistant to any of the anti-TB drugs than were the T2 strains (ORadj, 1.7; 95% CI, 1.0 to 2.9; P= 0.040). There were no significant associations between multidrug resistance and MTC lineages, but numbers of multidrug-resistant TB strains were small. No association was established between MTC lineages and HIV status. In conclusion, the T2 MTC lineage negatively correlates with anti-TB drug resistance, which might partly explain the reported low levels of anti-TB drug resistance in Kampala, Uganda. Patients' HIV status plays no role with respect to the MTC lineage distribution.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results